Gemcitabine Accord 100 mg/ml Koncentrat till infusionsvätska

DRUG2 trials

Sponsors

Vastra Gotalandsregionen, Region Skane, Region Skane

Conditions

Advanced pancreatic cancerPrimary or recurrent non-muscle invasive bladder cancer with intermediate risk of recurrence after transurethral tumour resection

Phase 3

Standard versus Prolonged Neoadjuvant (Conversion) Chemotherapy to prolong survival of patients with Borderline and Locally Advanced Pancreatic Cancer: a phase III randomized controlled trial; ADVANTAGE

RecruitingCTIS2022-502117-29-00

Vastra GotalandsregionenAdvanced pancreatic cancer

Start: 2023-10-19Target: 754Updated: 2025-12-15

Adjuvant instillations in intermediate risk NMIBC: A Study comparIng Gemcitabine and MitomYciN (SIGYN-trial)

Active, not recruitingCTIS2023-504945-30-00

Region Skane, Region SkanePrimary or recurrent non-muscle invasive bladder cancer with intermediate risk of recurrence after transurethral tumour resection

Start: 2021-03-16Target: 340Updated: 2024-08-30